BEGIN:VCALENDAR VERSION:2.0 PRODID:-//European Brain Council (EBC) - ECPv6.15.19//NONSGML v1.0//EN CALSCALE:GREGORIAN METHOD:PUBLISH X-WR-CALNAME:European Brain Council (EBC) X-ORIGINAL-URL:https://www.braincouncil.eu X-WR-CALDESC:Events for European Brain Council (EBC) REFRESH-INTERVAL;VALUE=DURATION:PT1H X-Robots-Tag:noindex X-PUBLISHED-TTL:PT1H BEGIN:VTIMEZONE TZID:UTC BEGIN:STANDARD TZOFFSETFROM:+0000 TZOFFSETTO:+0000 TZNAME:UTC DTSTART:20210101T000000 END:STANDARD END:VTIMEZONE BEGIN:VEVENT DTSTART;VALUE=DATE:20220604 DTEND;VALUE=DATE:20220608 DTSTAMP:20260415T053721 CREATED:20211115T143529Z LAST-MODIFIED:20220630T104116Z UID:32485-1654300800-1654646399@www.braincouncil.eu SUMMARY:30th European Congress of Psychiatry DESCRIPTION:  \nThe 30th European Congress of Psychiatry\, organised by the largest association of psychiatrists in Europe\, took place virtually on 4-7 June 2022. \nLinking Clinical Practice and Research for Better Mental Health Care in Europe. This was the guiding motto for the next edition of the EPA Congress. \nAn opportunity to engage with state-of-the-art clinical tools\, to expand the frontiers of research\, explore innovative ideas for mental health care and prevention with a community of global professionals and stakeholders in the field of psychiatry and mental health care. \nEBC was delighted to present: \n\nEuropean Brain Research Area (EBRA) at the 8th EPA Forum\nValue of Treatment (VOT) Symposium on Mental Health\nAutism Care Pathway in Europe\n\nFind more information about the EPA Congress here! URL:https://www.braincouncil.eu/event/30th-european-congress-of-psychiatry/ LOCATION:Budapest\, Hungary END:VEVENT BEGIN:VEVENT DTSTART;VALUE=DATE:20220604 DTEND;VALUE=DATE:20220608 DTSTAMP:20260415T053721 CREATED:20220425T101931Z LAST-MODIFIED:20220429T121423Z UID:36029-1654300800-1654646399@www.braincouncil.eu SUMMARY:Value of Treatment Symposium on Mental Health | 30th European Congress of Psychiatry DESCRIPTION:Recent studies underscore the severity of the mental health challenges children and adolescents face that can lead to high disability. There are numerous unmet needs along the care pathways\, although effective early detection and interventions exist. Navigating the mental health services system is often complex for families\, due to fragmented or disrupted services. \nThe Value of Treatment for Brain Disorders (VOT) is a health economics and outcomes research project coordinated by the European Brain Council. The second round (VOT2) on new therapeutic areas (anorexia nervosa\, autism spectrum disorder and major depressive disorder) was launched in 2019. This semester will be an important milestone in terms of case study results dissemination. The study looked at early intervention and explored the benefits of improved detection\, continuity of care and treatment\, and collaborative care patterns (also addressing mental health problems with comorbid medical conditions) on outcomes to patients and costs. Case studies which combine a care pathway analysis followed by an economic evaluation were conducted with the support of Academic Partners\, applying empirical evidence from different European countries.  \nThe European Brain Council (EBC) and the European Psychiatric Association (EPA) will convene a meeting at the upcoming EPA Congress 2022 to address challenges especially from the health economics perspective. Study results from VOT2 case studies on anorexia nervosa\, autism spectrum disorder and major depressive disorder\, will be showcased. In this symposium\, we report the findings of the groups of the Value of Treatment initiative and contextualise these by highlighting the limitations of existing economic models; the gaps in data availability; current research to address these gaps as well as directions for future research that will improve our ability to make the economic case for investment as well as our understanding of the patient experience and journey.  URL:https://www.braincouncil.eu/event/value-of-treatment-symposium-on-mental-health-30th-european-congress-of-psychiatry/ END:VEVENT BEGIN:VEVENT DTSTART;VALUE=DATE:20220604 DTEND;VALUE=DATE:20220608 DTSTAMP:20260415T053721 CREATED:20220429T121209Z LAST-MODIFIED:20220429T121428Z UID:36146-1654300800-1654646399@www.braincouncil.eu SUMMARY:Autism Care Pathway in Europe | European Congress of Psychiatry DESCRIPTION:The 30th European Congress of Psychiatry\, organised by the largest association of psychiatrists in Europe\, will take place virtually on 4-7 June 2022. \nEBC looks forward to presenting the case study on autism spectrum disorder (ASD) as part of the Value of Treatment (VOT) project: \nBackground: Autism is a lifelong complex neurodevelopmental condition that affects brain development and behaviour with significant consequences for everyday life.  Despite its personal\, familial\, and societal impact\, Europe-wide harmonised guidelines are still lacking for early detection\, diagnosis\, and intervention\, leading to an overall unsatisfactory autistic person and carer journey. ​  \nMethods:  The care pathway for autistic children and adolescents was analysed in Italy\, Spain and the United Kingdom (UK) from the perspective of carers\, the autistic community\, and professionals in order to identify major barriers (treatment gaps) preventing carers from receiving information\, support\, and timely screening/diagnosis and intervention. ​  \nResults: Across all three countries\, analysis of the current care pathway showed: long waits from the time carers raised their first concerns about a child’s development and/or behaviour until screening and confirmed diagnosis; delayed or no access to intervention once a diagnosis was confirmed; limited information about autism and how to access early detection services; and deficient support for families throughout the journey. ​  \nConclusions: These findings call for policy harmonisation in Europe to shorten long wait times for diagnosis and intervention and therefore\, improve autistic people and their families’ journey experience and quality of life.  URL:https://www.braincouncil.eu/event/autism-care-pathway-in-europe-european-congress-of-psychiatry/ END:VEVENT BEGIN:VEVENT DTSTART;TZID=UTC:20220604T090000 DTEND;TZID=UTC:20220604T120000 DTSTAMP:20260415T053721 CREATED:20220328T133047Z LAST-MODIFIED:20220425T104134Z UID:35190-1654333200-1654344000@www.braincouncil.eu SUMMARY:European Brain Research Area (EBRA) at the 8th European Psychiatric Association (EPA) Forum DESCRIPTION:EBC\, as project coordinators\, will present the European Brain Research Area (EBRA) project at the upcoming 8th European Psychiatric Association (EPA) Forum (taking place at the upcoming European Congress on Psychiatry 2022)\, centred around “Mental Health Care and Research in Europe: From Bench to Bedside and Back”. The Forum will take place on Saturday\, 4 June 2022\, 9:00-12:00 CEST at the congress venue in Budapest\, Hungary. The project will be presented by EBC Executive Director\, Frédéric Destrebecq. \nThe EPA Forum traditionally precedes the official opening of the annual European Congress on Psychiatry and aims to bring together EPA members and Congress delegates with European organisations\, stakeholders and policy makers in the field of mental health and mental health care to present and discuss matters of European importance. This year’s programme will focus on the role of research and evidence-based policies to improve mental health care in the EU. In this regard\, the EBRA project achievements\, namely the recently released landscape analysis on brain research (mapping report) and upcoming Shared European Brain Research Agenda (SEBRA) will be presented. URL:https://www.braincouncil.eu/event/ebra-at-the-8th-epa-forum/ END:VEVENT BEGIN:VEVENT DTSTART;TZID=UTC:20220623T140000 DTEND;TZID=UTC:20220623T160000 DTSTAMP:20260415T053721 CREATED:20220622T092244Z LAST-MODIFIED:20220622T092808Z UID:37643-1655992800-1656000000@www.braincouncil.eu SUMMARY:Preparing Europe for Novel Psychedelic-Assisted Therapies: Launch of PAREA DESCRIPTION:We all know the feeling of helplessness when we are unable to help people – often our loved ones – who are affected by mental health conditions\, addictions or neurological ailments\, including chronic pain. We know that mental healthcare is in crisis and we don’t have enough options to truly help many people in need. While it is true that there are many people who wouldn’t be here if it weren’t for antidepressants\, there are also millions who are on them and continue to struggle or experience serious side effects. Moreover\, the global expenditure on mental health amounts to a mere 2% of general expenditure (WHO\, 2021) and only a minority of people with mental health conditions in Europe receive treatment. We have a long way to go in improving mental health care\, and in achieving the relevant UN Sustainable Development Goals by 2030. \nAgainst this backdrop\, psychedelic-assisted therapies (PAT) show a promise of being a potent new class of treatments for mental\, neurological and substance use disorders\, as suggested by the rapidly growing\, rigorous\, and compelling body of research. \nIn 2021 alone\, ground-breaking findings were published in journals such as Lancet\, Nature and New England Journal of Medicine. Top tier US universities like NY University\, Johns Hopkins and the University of California are following the example of Imperial College London in the UK\, which in 2019 became the first to establish a centre dedicated to the study of psychedelic compounds. \nDuring 2017 – 2019\, the US FDA granted Breakthrough Therapy designation to PAT for three trials investigating psilocybin for depression and MDMA for PTSD. \nThe fundamental therapeutic benefit of PAT comes from the combination of psychedelic medicine and therapy. The drug is a catalyst for treatment\, not a treatment in itself. Patients report that they get something deeply meaningful out of the altered consciousness – a sense of unity\, of connection. Therapy allows them to incorporate that into an enduring shift in identity and to build a better self. In other words\, psychedelics’ novel therapeutic value stems from their role as enhancements to a psychotherapeutic process\, grounded in a relationship-centred approach\, that views mental health through a biopsychosocial lens. \nThe renaissance of research into the neuroscience and therapeutic applications of PAT represents one of the most promising and important initiatives in brain science and neuropsychopharmacology in recent times\, especially given the huge unmet needs in the therapeutic areas that they promise to treat. \nAt the same time\, much has to be done in Europe to start accommodating those advances and to accelerate the safe and responsible integration of PAT into EU healthcare systems in the years to come. This work must start now. \nWith this in mind\, the Psychedelic Access and Research European Alliance – PAREA was born. We bring together 15 members\, including EU patient advocacy groups in the field of mental health\, neurology and chronic pain\, scientific associations – neuropsychopharmacologists and cancer societies\, psychedelic foundations\, as well as industry partners. \nWe will be launching this partnership on 23rd June\, 2pm – 4pm CEST. See agenda below: \nPAREA agenda URL:https://www.braincouncil.eu/event/37643/ END:VEVENT BEGIN:VEVENT DTSTART;VALUE=DATE:20220625 DTEND;VALUE=DATE:20220629 DTSTAMP:20260415T053721 CREATED:20211115T145110Z LAST-MODIFIED:20211116T140619Z UID:32492-1656115200-1656460799@www.braincouncil.eu SUMMARY:8th Congress of the European Academy of Neurology DESCRIPTION:  \nThe 8th Congress of the European Academy of Neurology (EAN) will take place in Vienna (Austria) on June 25 to 28\, 2022. \nOur ambition is that the 8th EAN Congress will be a truly pan-European meeting\, in a fact the premier meeting of 2022\, bringing together neurologists and neuro-scientists to network and to exchange knowledge to tackle major challenges in neurology. In previous years EAN congresses have highlighted the developments in the host nation\, but in 2022\, following virtual congresses in 2020 and 2021\, we will break with that tradition. We have planned a meeting with a pan-European flavor\, celebrating the opportunity to meet once more in person in a hybrid meeting that will also maximise virtual participation\, building on our experience in 2020 and 2021. \nOur common European cultural heritage is rooted in innumerable domains: art\, architecture\, film\, philosophy\, literature\, and music to name a few. From a historical perspective\, we also know that great strides in neurology can be attributed European scientists such as Golgi\, Brown-Séquard\, and Romberg. The EAN is confident that the scientific contributions of European experts today will  continue to shape the field of neurology. \nThe overarching theme of the 2022 EAN congress is “Getting Evidence Into Practice”. Topics will include: Which clinical trial designs best inform practice? What evidence informs the use of diagnostic tests? Are guidelines a useful tool for improving outcomes? How do we get guidelines applied and implemented? These questions are timely and relevant\, and we are excited to hear from selected experts from neurology and other disciplines. As with every year\, leading specialists will share the most recent state-of-the-art studies and the newest developments in neurology\, and we invite all participants ask questions in the live Q&A sessions. \nFind more information here! URL:https://www.braincouncil.eu/event/8th-congress-of-the-european-academy-of-neurology/ LOCATION:Vienna\, Austria END:VEVENT BEGIN:VEVENT DTSTART;VALUE=DATE:20220625 DTEND;VALUE=DATE:20220629 DTSTAMP:20260415T053721 CREATED:20220318T155450Z LAST-MODIFIED:20220701T114040Z UID:34944-1656115200-1656460799@www.braincouncil.eu SUMMARY:EBC at EAN Congress 2022 DESCRIPTION:EBC was pleased to be part of this year’s Congress of the European Academy of Neurology\, which took place in person on 25-28 June 2022 in Vienna\, Austria. Alongside an Exhibition Stand in the EAN Neurohood\, EBC had a Special Session take place on 28 June at 13:00-14:30 (Room Berlin)\, celebrating 20 Years of Advocacy for the Brain. The session featured the following presentations: \nIntroduction & Moderation by Prof. Wolfgang Oertel\, President\, European Brain Council\nHistory of the European Brain Council by Prof. Jes Olesen\, Founding President\, European Brain Council\nInvolving patients and the Value of Treatment by Joke Jaarsma\, Treasurer\, European Brain Council and President\, European Federation of Neurological Associations\nAdvocating for the brain: the European Brain Research Area by Frédéric Destrebecq\, Executive Director\, European Brain Council \n  \n  \n\n \n \n \n \n \n \n EBC President\, Prof Wolfgang Oertel\, gives introductory presentation on EBC and to key moments in its 20-year history\n \n \n \n \n \n EBC Treasurer\, Joke Jaarsma\, reflects on 20 years of partnership between EBC and the European Federation of Neurological Associations\, a key member of EBC and patient representatives in the field of neurology.\n \n \n \n \n \n Prof Jes Olesen\, Founding President of EBC\, looks back on the last 20 years and the growth of the organisation since its humble beginnings.\n \n \n \n \n \n EBC Executive Director\, Frédéric Destrebecq\, provides insight on the important advocacy work done by EBC to culminate in its latest large-scale project\, the European Brain Research Area (EBRA)\n \n \n\n  \n  \nAdditionally\, EBC projects such as the European Brain Research Area (EBRA) and the Value of Treatment were showcased at the congress in the Scientific Theatre and through ePosters. \nScientific Theatres:\n– EBC Value of Treatment (VOT) Study – Bridging gaps and achieving seamless\, coordinated care\, a study on rare neurological and neurometabolic disorders by the European Brain Council – 25 June 2022\, 14:00 – 14:30 (Theatre 09)\n– EBC Value of Treatment (VOT) Study – A Comparison of Optimal Management vs Current Management of Chronic Pain– 27 June 2022\, 10:00-10:30 (Theatre 25)\n– European Brain Research Area (EBRA): Outcome and results of the Horizon 2020 project – 28 June 2022\, 10:30-11:00 (Theatre 37)\n \nePosters:\n– EBC Value of Treatment (VOT) Study – A Comparison of Optimal Management vs Current Management of Chronic Pain – 26 June 2022\, 12:30 to 13:15 (Screen B7)\n– EBC Value of Treatment (VOT) Study – Assessing the Value of Specialist Centres for the Diagnosis and Management of the Ataxias in Europe – 26 June 2022\, 12.30-13.15 (Screen A9) \n  \n  \n\n \n \n \n \n \n \n Vinciane Quoidbach\, EBC Research Project Manager\, presents the Value of Treatment – Chronic Pain study at the Scientific Theatre\n \n \n \n \n \n Views of the congress space\n \n \n \n \n \n Prof Paola Giunti presents the Value of Treatment Ataxia study at the Scientific Theatre\n \n \n \n \n \n EBC Staff in the Neurohood\n \n \n \n \n \n EBC Project Manager\, Dr Kristien Aarts\, presents the European Brain Research Area (EBRA) project at the Scientific Theatre URL:https://www.braincouncil.eu/event/ebc-at-ean-congress-2022/ END:VEVENT BEGIN:VEVENT DTSTART;TZID=UTC:20220627T140000 DTEND;TZID=UTC:20220701T173000 DTSTAMP:20260415T053721 CREATED:20220408T084448Z LAST-MODIFIED:20220408T085256Z UID:35467-1656338400-1656696600@www.braincouncil.eu SUMMARY:11th European Conference on Rare Diseases & Orphan Products DESCRIPTION:The European Conference on Rare Diseases & Orphan Products (ECRD) is recognised globally as the largest\, patient-led rare disease event in which collaborative dialogue\, learning and conversation takes place\, forming the groundwork to shape goal-driven rare disease policies and allow for important and innovative discussions on a national and an international level to take place. ECRD 2022 will take place online on 27 June -1 July. \nLeading\, inspiring and engaging all stakeholders to take action\, the Conference is an unrivalled opportunity to network and exchange invaluable knowledge with over 1500 stakeholders in the rare disease community – patient advocates\, policy makers\, researchers\, clinicians\, healthcare professionals\, healthcare industry representatives\, academics\, payers\, regulators and Member State representatives. \nEBC is pleased to take part in the 2022 ECRD as an Associate Partner. \nFind out all the conference details – including programme – through the official website. Registration for the conference is open and the deadline for Poster Submissions has been extended until 21 April. \n  URL:https://www.braincouncil.eu/event/11th-european-conference-on-rare-diseases-orphan-products/ END:VEVENT END:VCALENDAR